Table 7. C-index analysis of the prognostic accuracy of RNF43, YAP and other variables for overall survival and progression-free survival in all cohorts.
| C-index (95% CI) | Overall survival | Progression-free survival | ||||||
|---|---|---|---|---|---|---|---|---|
| Cohort 1 (n = 193) | Cohort 2 (n = 127) | Training Cohort (n = 160) | Validation Cohort (n = 160) | Cohort 1 (n = 193) | Cohort 2 (n = 127) | Training Cohort (n = 160) | Validation Cohort (n = 160) | |
| TNM stage | 0.716 (0.697–0.835) | 0.701 (0.622–0.781) | 0.709 (0.643–0.774) | 0.722 (0.632–0.812) | 0.69 (0.616–0.775) | 0.687 (0.718–0.757) | 0.703 (0.620–0.786) | 0.704 (0.633–0.814) |
| SSIGN | 0.704 (0.624–0.784) | 0.729 (0.675–0.783) | 0.74 (0.695–0.785) | 0.703 (0.624–0.783) | 0.681 (0.606–0.756) | 0.707 (0.642–0.772) | 0.725 (0.6735–0.777) | 0.671 (0.624–0.819) |
| RNF43 | 0.766 (0.674–0.857) | 0.797 (0.702–0.892) | 0.777 (0.688–0.865) | 0.778 (0.670–0.885) | 0.748 (0.656–0.840) | 0.800 (0.709–0.892) | 0.76 (0.671–0.850) | 0.756 (0.660–0.852) |
| YAP | 0.785 (0.695–0.874) | 0.676 (0.553–0.800) | 0.76 (0.668–0.852) | 0.732 (0.604–0.861) | 0.772 (0.670–0.875) | 0.671 (0.537–0.805) | 0.76 (0.665–0.855) | 0.695 (0.551–0.839) |
| RNF43 + YAP | 0.796 (0.722–0.870) | 0.8 (0.696–0.904) | 0.806 (0.705–0.907) | 0.783 (0.687–0.878) | 0.777 (0.694–0.861) | 0.806 (0.735–0.878) | 0.792 (0.717–0.867) | 0.763 (0.660–0.867) |
| RNF43 + YAP + TNM stage | 0.846 (0.785–0.908) | 0.876 (0.823–0.929) | 0.847 (0.786–0.908) | 0.865 (0.797–0.933) | 0.839 (0.775–0.903) | 0.885 (0.831–0.939) | 0.834 (0.769–0.900) | 0.865 (0.806–0.924) |
| RNF43 + YAP + SSIGN | 0.851 (0.784–0.919) | 0.873 (0.803–0.942) | 0.833 (0.759–0.906) | 0.905 (0.846–0.963) | 0.848 (0.775–0.921) | 0.895 (0.840–0.950) | 0.827 (0.753–0.901) | 0.895 (0.836–0.955) |